论文部分内容阅读
异位ACTH综合症是最早描述的异位体液综合症,其特征是非内分泌腺肿瘤产生ACTH样物质。继发于异位产生ACTH的柯兴氏综合症病人中,肺癌病人占一半,而早期肺癌中柯兴氏症的发生率是0.4-2%。所有无柯兴氏症的肺癌病人,其癌组织提取物内含有相当高浓度的免疫反应性的ACTH。它主要是分子量为20000的大分子。这种“大ACTH”经胰酶消化,便释放出分子量为4500的ACTH。所以大分子量的ACTH可能是ACTH的前身;被称为ACTH原(Pro ACTH)。 ACTH原是糖肽,若肺癌细胞将这种无生物活性的ACTH分泌到血液内,则可作为一种有用的肿瘤标记,用于肺癌的早期检测。
The ectopic ACTH syndrome is the earliest description of ectopic humoral syndrome, characterized by the production of ACTH-like substances from non-endocrine tumors. Patients with Cushing’s Syndrome secondary to ectopic ACTH production accounted for half of lung cancer patients, and the incidence of Cushing’s disease in early stage lung cancer was 0.4-2%. All patients with lung cancer without Cushing’s disease, the cancer tissue extract contains a relatively high concentration of immunoreactive ACTH. It is mainly a macromolecule with a molecular weight of 20,000. This “big ACTH” was digested with trypsin and released ACTH with a molecular weight of 4,500. Therefore, the large molecular weight ACTH may be the predecessor of ACTH; it is called Pro ACTH. ACTH is originally a glycopeptide. If lung cancer cells secrete this inactive biological ACTH into the blood, it can be used as a useful tumor marker for the early detection of lung cancer.